Clearside Biomedical, Inc., CLSD is showing recent insider trading activity. Public SEC records indicate that BRADFORD WHITMORE recently Bought $599,999 worth of shares on 3 weeks ago. With that said, our editors here at politicsandwallstreet.com, are adding CLSD to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of CLSD that Sold 1,597 worth of shares in the last 3 months, the Insider Confidence level of Clearside Biomedical, Inc. is trending Down.
Since these insiders have unique insights into what's happening at Clearside Biomedical, Inc., this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for CLSD:
In addition, TradingView issued a Strong buy rating for CLSD over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook.
Here is a bit more on Clearside Biomedical, Inc., CLSD but please do your own research.
CLSD Summary: Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to CLSD, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of CLSD that Sold 1,597 worth of shares in the last 3 months, the Insider Confidence level of Clearside Biomedical, Inc. is trending Down.
Since these insiders have unique insights into what's happening at Clearside Biomedical, Inc., this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for CLSD:
- BRADFORD WHITMORE - director, officer: CEO, Bought $599,999 worth of shares on 2 days ago
- GEORGE LASEZKAY - 10 percent owner, Sold $22,860 worth of shares on 3 weeks ago
- Charles Deignan - officer: Chief Financial Officer, Sold $16,512 worth of shares on 3 weeks ago
- BRADFORD WHITMORE - 10 percent owner, Bought $47,901 worth of shares on 3 months ago
In addition, TradingView issued a Strong buy rating for CLSD over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook.
Here is a bit more on Clearside Biomedical, Inc., CLSD but please do your own research.
CLSD Summary: Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
- Recent Last Price: $1.42
- Price Change: $0.04, 2.90%
- Yearly Gain: 4.41%
- Market Cap: $88.62M
- P/E Ratio: -2.33
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to CLSD, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
